New combo pill aims to supercharge weight loss in obesity

NCT ID NCT07505303

Ongoing Disease control Sponsor: Eccogene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2a trial tests whether adding an oral drug called ECC4703 to the weekly injection semaglutide helps adults with obesity lose more weight and reduce liver fat. About 151 participants will take either ECC4703 or a placebo alongside semaglutide for 20 weeks. The study is active but no longer recruiting, and results will show if the combination is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ECC4703 (oral drug) added to semaglutide (injectable drug)
What this could lead to: If it works, this could lead to a more effective weight-loss treatment by combining two drugs, potentially helping people with obesity lose more weight and reduce liver fat.
What could go wrong: This is an early Phase 2a trial with only 151 people, so results may not apply to everyone. The drug combination could cause side effects, and it's not yet known if it works better than semaglutide alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT OBESITY WEIGHT MANAGEMENT

Contacts and locations

Locations

AES - DRS - Optimal Research Florida - Melbourne

Melbourne, Florida, 32934, United States
AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis

Richfield, Minnesota, 55423, United States
AES - DRS - Synexus Clinical Research US, Inc. - San Antonio

San Antonio, Texas, 78229, United States
Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS

Anaheim, California, 92081, United States
Atlanta Center for Medical Research - CenExel ACMR - PPDS

Atlanta, Georgia, 30331, United States
Central Research Associates - Flourish - PPDS

Birmingham, Alabama, 35205, United States
Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS

Los Alamitos, California, 90720, United States
Flourish Research - San Antonio - PPDS

San Antonio, Texas, 78229, United States
ForCare Clinical Research - CenExel FCR - PPDS

Tampa, Florida, 33613, United States
Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS

Omaha, Nebraska, 68134, United States
Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS

Cincinnati, Ohio, 45246, United States
Velocity Clinical Research - Dallas - PPDS

Dallas, Texas, 75230, United States
Velocity Clinical Research - Durham - PPDS

Durham, North Carolina, 27701, United States
Velocity Clinical Research - Providence - PPDS

East Greenwich, Rhode Island, 02818, United States
iResearch Atlanta - CenExel - PPDS

Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.